No Data
No Data
Thursday, Halloween Market Falls in Scary Reaction to Earnings | Wall Street Today
Bristol-Myers Squibb Options Spot-On: On October 31st, 62,299 Contracts Were Traded, With 702.52K Open Interest
Bristol Myers Squibb Announced Topline Data From Its Phase 3 Study Of COBENFY That Showed Continuing Improvement In Symptoms Of Schizophrenia
Bristol Myers Squibb Presents New Long-term Data From the EMERGENT Program Evaluating COBENFY (Xanomeline and Trospium Chloride) in Adults With Schizophrenia at Psych Congress 2024
Express News | Bristol Myers Squibb Presents New Long-Term Data From the Emergent Program Evaluating Cobenfy™ (Xanomeline and Trospium Chloride) in Adults With Schizophrenia at Psych Congress 2024
Earnings Call: Bristol-Myers Squibb Reports Robust Q3 Growth, Raises Guidance
No Data
No Data
1038116155 : Nyi Nyi Htwe Y324412